Two weeks of exercise alters neuronal extracellular vesicle insulin signaling proteins and pro-BDNF in older adults with prediabetes.
Steven K Malin, Daniel J Battillo, Michal S Beeri...
https://pubmed.ncbi.nlm.nih.gov/39421964/Actively Recruiting
Led by Rutgers, The State University of New Jersey · Updated on 2026-06-30
60
Participants Needed
4
Research Sites
1 weeks
Total Duration
Researchers are studying older adults aged 55 to 80 with Type 2 Diabetes to see if combining exercise with an insulin nose spray improves brain blood flow and thinking better than exercise alone. The study focuses on brain insulin resistance, which may impact memory and glucose control, and explores whether this combined approach can help the brain respond better to insulin. The trial is a randomized, phase 23 study aiming to understand effects on brain function and insulin sensitivity. Participants will be randomly assigned to one of two groups one will perform supervised high intensity exercise three times a week for 16 weeks while using an intranasal insulin spray twice daily, and the other will do the same exercise regimen but use a saline placebo spray. The exercise involves walking or light jogging at about 85% of each persons maximum oxygen intake, with sessions lasting around 60 minutes including warm-up and cool-down periods. The insulin or placebo is delivered by a special device as a 20-second stream into each nostril. During the study, participants will undergo brain scans, cognitive tests, blood tests, fitness evaluations, and body composition scans before and after the 16-week intervention. Researchers will measure changes in brain insulin sensitivity, blood brain barrier integrity, insulin signaling proteins, cognitive function, and other health markers. The study includes close monitoring to assess how well participants follow the exercise and treatment plan and to evaluate safety and outcomes.
CONDITIONS
Exercise and Intranasal Insulin in Type 2 Diabetes
S
Steven K Malin, PhD
E
Emily M Heiston, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Rutgers, The State University of New Jersey
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Exercise + Intranasal Insulin | Exercise + IN Placebo | Guideline‑Based Usual Care |
|---|---|---|---|
| What it is | High‑intensity aerobic exercise combined with intranasal insulin delivered via a nasal device twice daily for 16 weeks | High‑intensity aerobic exercise combined with intranasal placebo delivered via the same device and schedule | Evidence‑based diabetes management per ADA Standards of Care including lifestyle modification and pharmacologic therapy |
| Role in trial | Investigational arm combining exercise and intranasal insulin | Active control arm combining exercise with placebo intranasal spray | Not part of the trial but represents typical care outside trial enrollment |
| Primary purpose or use | To evaluate whether adding intranasal insulin to high‑intensity exercise improves brain blood flow, insulin sensitivity, and cognitive function | To serve as comparison to isolate the effect of intranasal insulin when added to exercise | Represents usual disease management without investigational intervention |
| How it is given or performed | Supervised treadmill walking 3 times per week for 16 weeks, plus intranasal insulin twice daily using a nasal delivery device | Same supervised treadmill exercise schedule plus intranasal placebo twice daily via same device | Lifestyle guidance (diet, physical activity) plus pharmacologic treatment individualized per patient needs |
| Important risks | Potential insulin‑related hypoglycemia risk not well established via intranasal route | Minimal risk beyond exercise safety considerations | Safety profile established for approved diabetes therapies and lifestyle guidance when supervised |
| Important limitations | Small exploratory imaging studies; cognitive outcome benefit not yet proven in T2D populations | Does not test intranasal insulin; cannot determine additive effect beyond exercise alone | Does not include novel investigational approaches under study |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 16 weeks
Participants engage in supervised high intensity exercise three times per week for 16 weeks and use intranasal insulin or placebo spray twice daily.
3 visits per week for exercise supervision
Duration - Up to 2 weeks after treatment
Participants complete brain imaging, cognitive tests, blood tests, fitness assessments, and body composition scans before and after the intervention to evaluate changes.
2 visits for assessments
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Steven K Malin, Daniel J Battillo, Michal S Beeri...
https://pubmed.ncbi.nlm.nih.gov/39421964/Steven K Malin, Daniel J Battillo, David H Zald...
https://pubmed.ncbi.nlm.nih.gov/41978122/Steven K Malin, Daniel J Battillo, Michal S Beeri...
https://pubmed.ncbi.nlm.nih.gov/41876945/Steven K Malin, David H Zald, Daniel J Battillo
https://pubmed.ncbi.nlm.nih.gov/42295834/Rutgers, The State University of New Jersey
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor